Nephroprotektive Effekte des SGLT2-Inhibitors Empagliflozin
نویسندگان
چکیده
منابع مشابه
Mechanism of Action of Sglt2-inhibitors
T2DM individuals manifest a 2-3 times greater risk of CV events compared to non-diabetics, and CV mortality is responsible for ~70% of total mortality. In T2DM patients without MI, risk of CV death is similar to individuals without diabetes with prior MI.1 Although hyperglycemia is a strong risk factor for microvascular complications, it is a weak risk factor for CV disease (CVD), and intervent...
متن کاملSGLT2 Inhibitors and the Diabetic Kidney.
Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, the most recent glucose-lowering oral agents, may have the potential to exert nephroprotectio...
متن کاملThe SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
Hyperglycemia associated with inflammation and oxidative stress is a major cause of vascular dysfunction and cardiovascular disease in diabetes. Recent data reports that a selective sodium-glucose co-transporter 2 inhibitor (SGLT2i), empagliflozin (Jardiance®), ameliorates glucotoxicity via excretion of excess glucose in urine (glucosuria) and significantly improves cardiovascular mortality in ...
متن کاملSchlaganfall bei Normotensiven und Hypertensiven Ratten: Effekte von Lithium und Hemmstoffen des Renin-Angiotensin-Systems
I declare that this thesis has not been submitted in any form for another degree or diploma at any university. Results discussed in this thesis are my own work, and information derived from the literature or unpublished work of others has been acknowledged in the text and a list of references provided. II CONTENTS Page 1 Introduction 1 1.1 Stroke and animal models of stroke 1 1.1.1 Stroke-prone...
متن کاملSodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents
Although several treatment options are available to reduce hyperglycemia, only about half of individuals with diagnosed diabetes mellitus (DM) achieve recommended glycemic targets. New agents that reduce blood glucose concentrations by novel mechanisms and have acceptable safety profiles are needed to improve glycemic control and reduce the complications associated with type 2 diabetes mellitus...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diabetes aktuell
سال: 2018
ISSN: 1861-6089,1864-1733
DOI: 10.1055/a-0791-3169